The soluble guanylyl cyclase activator BAY 60-2770 ameliorates detrusor dysfunction in obese mice by Nucci, Gilberto de et al.
  Universidade de São Paulo
 
2013
 
The soluble guanylyl cyclase activator BAY
60-2770 ameliorates detrusor dysfunction in
obese mice
 
 
BMC Pharmacology and Toxicology 2013, 14(Suppl 1):P18 doi:10.1186/2050-6511-14-S1-P18
http://www.producao.usp.br/handle/BDPI/33239
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Farmacologia - ICB/BMF Artigos e Materiais de Revistas Científicas - ICB/BMF
POSTER PRESENTATION Open Access
The soluble guanylyl cyclase activator BAY
60-2770 ameliorates detrusor dysfunction
in obese mice
Gilberto de Nucci1,2*, Luiz Osorio Leiria1, Fábio Henrique da Silva1, Eduardo C Alexandre1, Marina Calixto1,
Fabíola Zakia Mónica1, Edson Antunes1
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany. 28-30 June 2013
Background
The obesity-associated insulin resistance has been shown to
play an important role in the pathophysiology of overactive
bladder in mice [1,2]. Therefore, we evaluated the beneficial
effects of long-term administration of the sGC activator
BAY 60-2270 in bladders from lean and obese mice.
Methods
Mice were fed for 12 weeks with either a standard chow
diet (carbohydrate: 70%; protein: 20%; fat: 10%) or a high
fat diet that induces obesity (carbohydrate: 29%; protein:
16%; fat: 55%). Lean and obese mice were orally treated
with BAY 60-2770 (1 mg/kg/day, given as daily gavage
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Figure 1 Concentration response curve to cabachol (0.001-100 µM) in isolated bladder from lean and obese mice that received or not BAY 60-
2770 (1 mg/Kg, 2 weeks). Data represent mean ± S.E.M.
de Nucci et al. BMC Pharmacology and Toxicology 2013, 14(Suppl 1):P18
http://www.biomedcentral.com/2050-6511/14/S1/P18
© 2013 de Nucci et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
from the 10th to the 12th week) or its vehicle (Transcutol®:
Cremophor®:water, 1:2:7, v/v/v). Concentration-response
curves to full agonist carbachol (CCh, 0.001-100 µM) were
obtained. The values of potency (pEC50) and maximal
responses (Emax) were calculated. The cGMP levels and
Western blotting for a1 and b1-subunit of sGC in the
bladder tissues were also determined.
Results
Contractile response to the muscarinic agonist carbachol
was greater (p<0.05, n=5) in bladder from the obese in
comparison with lean group. Long-term treatment with
BAY 60-2770 normalized the enhanced contractile
responses of the obese group, driving it to control levels
(p<0.05; figure 1). The cGMP levels in the bladder tissues
from obese group were significantly lower in comparison
with lean mice (0.27 ± 0.04 and 0.95 ± 0.14 pmol/mg
tissue, respectively, p<0.05, n=5). Treatment with BAY 60-
2770 generated a 10-fold increase (p<0.01) in the bladder
cGMP levels of obese mice, without affecting the levels in
the lean group (Figure 2A). Protein expression of a1 and
b1 subunits of sGC was decreased by 41% and 43%
(p<0.05) in bladder tissues of obese animals, respectively.
However, oral treatment with BAY 60-2770 restored the
protein levels of a1 and b1 subunits to that of lean group
(Figure 2B and 2C).
Conclusion
Chronic treatment with BAY 60-2770 results in ameli-
oration of bladder dysfunction in high-fat obese mice.
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Figure 2 Effect of chronic treatment with BAY 60-2770 (1 mg/kg, 2 weeks) on cGMP levels (A) and protein expression of a1 (B) and b1 (C)
subunits of sGC in bladders from lean + vehicle, lean + BAY 60-2770, obese + vehicle and obese + BAY 60-2770 groups. Data are presented as
mean ± SEM. ★p <0.05 in comparison with lean + vehicle group; †p <0.05 in comparison to obese + vehicle group.
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